Progentos Therapeutics' CEO Chris Loose (L) and Chief Scientific Officer Sanjay Magavi

Prog­en­tos emerges with $65M for mul­ti­ple scle­ro­sis tri­als with IP from Fre­quen­cy

A new biotech emerged to take for­ward the lead pre­clin­i­cal work de­vel­oped by Fre­quen­cy Ther­a­peu­tics, a re­gen­er­a­tive med­i­cines com­pa­ny that gave up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.